'The Facts'

The facts on workplace flexibility December 10, 2018

AbbVie's Kirsten O'Doherty and AstraZeneca's Kimberly Elliott both highlighted the importance of workplace flexibility in separate interviews with PharmaDispatch about the gender equity-focused PAGE initiative. What are the facts?

The real impact of the 'deferral' policy July 31, 2018

The political debate on the PBS has significantly focussed on the former 'deferrals' policy - what was the impact and does it matter as much as it did?

Health system far from a 'money pit' July 7, 2016

One of the fundamental weaknesses in the Coalition's approach to health policy is that it has been driven by a publicly expressed concern over growth in spending that is not supported by the facts.

Spending shift from F2 to F1 May 6, 2016

The 2014-15 PBS Expenditure and Prescriptions Report has for the first time included the split of spending and prescription volumes between the F1 and F2 formularies.

Official report confirms fall in PBS spend May 5, 2016

The Department of Health has published the official 2014-15 PBS Expenditure and Prescriptions Report that reveals a 3.5 per cent decline in spending on the scheme.

No new savings but price disclosure savings forecast to hit $20 billion May 3, 2016

No new PBS price savings measures will bring relief for the pharmaceutical sector. However, the Government now expects savings from price disclosure to exceed a staggering $20 billion over the years to 2020.

Budget 2016-17 - the measures May 3, 2016

PBS, LSDP, vaccines and the National Blood Authority $12.3 million over five years to fund ORFADIN (nitisinone) through the LSDP. Continued funding for legal action to seek compensation for...

Where will the money come from? September 22, 2015

Unless the new reforms deliver another wave of unbudgeted PBS savings, finding the money for new listings in a system that is not growing will remain a challenge, made worse by things like $300 million downward revisions.

A list full of generics June 1, 2015

The reconstruction shows that around 60 per cent of the listings claimed by the Government are generics, and that some drugs have been counted multiple times, reflecting the number of new brands.

PBS share of health starts to rise May 18, 2015

PBS spending as a share of total health spending has fallen for the past five years, but the Budget has revealed that it's about to start rising.

PBS forecast revised up again May 13, 2015

The era of massive reform-driven downward revisions has definitely come to an end.

The ‘announced’ measures May 12, 2015

New listings, price cuts, the MRFF, while the Government is sticking with the proposed increase in PBS co-payments and Safety Net thresholds.

Latest Video

Most Read

Patients might be hoping their medicine belongs to a large company

The 'post-rebate' era has started with or without supply chain reform

Is there even a plan for emerging therapies in Australia?

Government could come for more given savings shortfall

Federal government still finalising CAR-T agreement with Peter Mac

New Stories

The 'post-rebate' era has started with or without supply chain reform

Is there even a plan for emerging therapies in Australia?

Federal government still finalising CAR-T agreement with Peter Mac

EBOS looking to 'the next wave of growth'

Bayer makes another move into cell therapy

Government could come for more given savings shortfall

Patients might be hoping their medicine belongs to a large company

Sign In

Latest Video

Most Read

Patients might be hoping their medicine belongs to a large company

The 'post-rebate' era has started with or without supply chain reform

Is there even a plan for emerging therapies in Australia?

Government could come for more given savings shortfall

Federal government still finalising CAR-T agreement with Peter Mac

Follow Us

New Stories

The 'post-rebate' era has started with or without supply chain reform

Is there even a plan for emerging therapies in Australia?

Federal government still finalising CAR-T agreement with Peter Mac

EBOS looking to 'the next wave of growth'

Bayer makes another move into cell therapy

Government could come for more given savings shortfall

Patients might be hoping their medicine belongs to a large company